Bristol Myers Squibb’s Cancer Drug Just Doubled Survival Time Without Progression — Here’s Why It Matters

Bristol Myers Squibb announced positive Phase 3 trial results for izalontamab brengitecan (iza-bren), an experimental cancer drug that doubled progression-free survival time (11.1 months vs. 5.7 months) compared to chemotherapy in non-small cell lung cancer patients. However, the stock reaction was muted because the trial was conducted only in China, and FDA approval typically requires multi-region confirmatory data meeting Western standards. The drug represents part of BMY's strategy to transition from legacy medications to a growth portfolio.